ABSTRACT
In December 2022, a total of 68 infectious diseases were reported globally, affecting 235 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were COVID-19 (235), monkeypox (110), dengue fever (28), measles (27) and cholera (14). The top five infectious diseases with highest case fatality rates were Ebola virus disease (47.0%), Rift Valley fever (44.2%), Crimean-Congo haemorrhagic fever (40.0%), Lassa fever (17.6%) and West Nile fever (7.6%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, cholera, dengue fever and measles. The prevalent infectious diseases in Asia were COVID-19, cholera and dengue fever, the prevalent infectious diseases in Africa were COVID-19, cholera, yellow fever, Lassa fever, monkeypox, malaria and measles, the prevalent infectious diseases in America were COVID-19, cholera, monkeypox, dengue fever and chikungunya fever, the prevalent infectious disease in Europe were COVID-19, monkeypox and invasive group A streptococcus infection.
ABSTRACT
Vaccination is effective in preventing the increase of disease, especially emerging infectious diseases (EIDs), and it is particularly important for people in close contact with infected sources and susceptible populations who are at increased risk of getting infectious diseases due to behavior, occupation or health. Despite targeted vaccination guidelines, inadequate vaccination of the key populations fails to receive widespread attention, resulting in a high-risk transition of disease from key populations to general populations. Strengthening the vaccination of the susceptible groups can effectively block the spread of pathogens to general populations, and reduce the consumption of medical resources in universal vaccination, which has significant economic value. In this review, we describe the prevalence of EIDs, analyze the experience and lessons of infectious disease vaccination in key populations through several cases, and further explore the causes for the decline in vaccination rates of key populations. According to the trends of EIDs, a plan to strengthen the vaccination of key populations is proposed to effectively prevent the transition of EIDs from key populations to general populations.
ABSTRACT
In December 2022 (from 00: 00, 1 December to 24: 00, 31 December), except COVID-19, a total of 278 907 cases of notifiable communicable diseases, including 2 384 deaths, were reported in China (except Hong Kong, Macao Special Administrative Regions and Taiwan Province, the same below). In communicable diseases in class A, no cases and no deaths were reported. In communicable diseases in class B, no cases and no deaths of severe acute respiratory syndrome, poliomyelitis, human infection with highly pathogenic avian influenza virus, diphtheria and human infection with avian influenza A (H7N9) virus were reported. For the remaining 21 communicable diseases except COVID-19 in class B, a total of 148 573 cases were reported, a decrease of 29% compared with last month (210 178 cases) and a decrease of 46% compared with the same period in 2021 (273 361 cases). The first 5 diseases in terms of reported case number were viral hepatitis, pulmonary tuberculosis, syphilis, gonorrhea and AIDS, accounting for 96% of the total reported cases in class B. A total of 2 384 deaths were reported, an increase of 28% (521 deaths) compared with last month (1 863 deaths) and a decrease of 14% compared with the same period in 2021 (2 763 deaths). In class C communicable diseases, a total of 130 334 cases were reported, a decrease of 33% compared with last month (195 072 cases) and a decrease of 69% compared with the same period in 2021 (420 015 cases). The first 3 diseases in terms of reported case number were influenza, other infectious diarrhea, and hand foot and mouth disease (HFMD), accounting for 96% of the total reported cases in class C. Compared with last month, except filariasis which had no incidence, the reported case number of leprosy was same, and the disease with reported case increase was echinococcosis (47 cases, 48%), the reported cases of other diseases all decreased, the first 3 diseases with reported case decreases were HFMD (22 886 cases, 45%), other infectious diarrhea (21 962 cases, 43%) and influenza (14 775 cases, 18%). Compared with the same period in 2021, except filariasis which had no incidence, the reported cases of other diseases all decreased, the first 3 diseases with reported case decreases were influenza (181 158 cases, 73%), other infectious diarrhea (53 502 cases, 65%) and HFMD (46 674 cases, 63%). No death caused by class C communicable disease was reported, same to last month and a decrease of 7 deaths compared with the same period in 2021 (7 deaths).
ABSTRACT
Yellow fever transmission in Africa included outbreaks and cases in countries with a history of YF mass vaccination campaigns (Cameroon, Central African Republic, Ghana), escalating the concern raised by the re-emergence of outbreaks in West Africa in 2020. In 2021, those outbreaks affected populations that had not been reached by immunization services, including people living in areas with compromised security and people missed in large-scale campaigns. The resurgence of intense viral transmission highlights the importance of achieving and maintaining equitable, high vaccination coverage of all at-risk populations. COVID-19 continued to impact YF control in 2021. The type of effect changed as countries prioritized vaccination against COVID-19, which led to postponement or de-prioritization of YF vaccination in some countries and affected vaccine acceptance. Despite the challenges, priority countries made good progress in implementing the Eliminate Yellow fever Epidemics (EYE) strategy in 2021, with >48 million people reached through reactive, catch-up and preventive YF vaccination campaigns in Africa.
ABSTRACT
More than 100 arboviruses, almost all of which have an RNA genome, cause disease in humans. RNA viruses are causing unprecedented health system challenges worldwide, many with little or no specific therapies or vaccines available. Certain species of mosquito can carry dengue virus (DENV), Zika virus (ZIKV) and yellow fever virus (YFV), where co-infection of these viruses has occurred. Here, we found that purified synthetic defective interfering particles (DIPs) derived from DENV type 2 (DENV-2) strongly suppressed replication of the aforementioned viruses, respiratory syncytial virus (RSV) and also the novel emerging virus SARS-CoV-2 in human cells. DENV DIPs produced in bioreactors, purified by column chromatography, and concentrated are virus-like particles that are about half the diameter of a typical DENV particle, but with similar ratios of the viral structural proteins envelope and capsid. Overall, DIP-treated cells inhibited DENV, ZIKV, YFV, RSV, and SARS-CoV-2 by at least 98% by mechanisms which included interferon (IFN)-dependent cellular antiviral responses. IMPORTANCE DIPs are spontaneously derived virus mutants with deletions in genes that block viral replication. DIPs play important roles in modulation of viral disease, innate immune responses, virus persistence and virus evolution. Here, we investigated the antiviral activity of highly purified synthetic DIPs derived from DENV, which were produced in bioreactors. DENV DIPs purified by column chromatography strongly inhibited five different RNA viruses, including DENV, ZIKV, YFV, RSV, and SARS-CoV-2 in human cells. DENV DIPs inhibited virus replication via delivery of a small, noninfectious viral RNA that activated cellular innate immunity, resulting in robust type 1 interferon responses. The work here presents a pathway for DIP production which is adaptable to Good Manufacturing Practice, so that their preclinical testing should be suitable for evaluation in subjects.
ABSTRACT
Introduction: Different classes of disease-causing viruses are widely distributed universally. Plant-based medicines are anticipated to be effective cures for viral diseases including the COVID-19, instigated by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This study displays the phylogenetic perspective of Artemisia and proposes some candidate taxa against different viral diseases, including SARS-CoV-2. Methods: Data of Artemisia with antiviral activity were obtained from different published sources and electronic searches. A phylogenetic analysis of the nrDNA ITS sequences of reported antiviral Artemisia species, along with the reference species retrieved from the NCBI GenBank database, was performed using the maximum likelihood (ML) approach. Results: In total, 23 Artemisia species have been documented so far with antiviral activity for 17 different types of viral diseases. 17 out of 23 antiviral Artemisia species were included in the ITS phylogeny, which presented the distribution of these antiviral Artemisia species in clades corresponding to different subgenera of the genus Artemisia. In the resultant ML tree, 10 antiviral Artemisia species appeared within the subgenus Artemisia clade, 2 species appeared within the subgenus Absinthium clade, 3 species appeared within the subgenus Dracunculus clade, and 2 species appeared within the subgenus Seriphidium clade. Discussion: Artemisia species from different subgenera with antiviral activity are prevalent in the genus, with most antiviral species belonging to the subgenus Artemisia. A detailed analysis of taxa from all subgenera, particularly the subgenus Artemisia, is therefore proposed in order to discover compounds with potential anti-SARS-CoV-2 activity.
ABSTRACT
Emerging and re-emerging zoonotic diseases cause serious illness with billions of cases, and millions of deaths. The most effective way to restrict the spread of zoonotic viruses among humans and animals and prevent disease is vaccination. Recombinant proteins produced in plants offer an alternative approach for the development of safe, effective, inexpensive candidate vaccines. Current strategies are focused on the production of highly immunogenic structural proteins, which mimic the organizations of the native virion but lack the viral genetic material. These include chimeric viral peptides, subunit virus proteins, and virus-like particles (VLPs). The latter, with their ability to self-assemble and thus resemble the form of virus particles, are gaining traction among plant-based candidate vaccines against many infectious diseases. In this review, we summarized the main zoonotic diseases and followed the progress in using plant expression systems for the production of recombinant proteins and VLPs used in the development of plant-based vaccines against zoonotic viruses.
ABSTRACT
In March 2022, a total of 63 infectious diseases were reported globally, affecting 230 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were COVID-19 (230), dengue fever (32), measles (29), chikungunya fever (10) and cholera (9). The top five infectious diseases with highest case fatality rates were Crimean-Congo haemorrhagic fever (33.3%), Rift Valley fever (20.0%), Lassa fever (18.6%), yellow fever (11.3%) and monkeypox (5.5%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, measles, cholera and Lassa fever. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, cholera, yellow fever, Lassa fever, malaria, measles and poliomyelitis, the prevalent infectious diseases in America were COVID-19, dengue fever and chikungunya fever, the prevalent infectious disease in Europe was COVID-19.
ABSTRACT
As a result of the scale of the Covid 19 pandemic that launched from China in December 2019 and to limit its spread, several treatments were used to control this virus, including, hydroxychloroquine, favipiravir, lopinavir, remidesivir, tocilizumab, and anakinra. Favipiravir is an antiviral drug that works by inhibiting RNA-dependent RNA polymerase, favipiravir inhibited viral genome replication, which was most noticeable in the middle of the viral proliferation period. Favipiravir was found to have antiviral activity, Purine nucleosides or purine bases inhibit favipiravir, meaning that it competes with purine nucleosides rather than pyrimidine nucleosides, In a time-of-drugaddition test, to treat a variety of RNA viruses (influenza, West Nile, yellow fever, flaviviruses, arenaviruses, bunyaviruses and alphaviruses). Here, we show for the first time the histologycal effect of favipiravir on the liver and kidneys using albino rats, using light microscopy, where the optical microscopic revealed that normal doses in liver showed hepatic cords arranged, normal central vein and mild sinusoildal infiltration of mono nuclear leukocytes mainly lymphocytes, the hepatocytes showed mild granular cytoplasm while double doses showed little hemorrhagic foci and disarrangement of hepatic cords. The magnified sections revealed few of hepatocytes showed mild cloudy swelling associated with little figures of cellular necrosis. As for kidneys, the optical microscopic observations showed multiple foci of hemorrhage, the magnified section revealed congestion of glomerular capillary tuft and few of renal tubules showed mild granular or vacular degeneration. On the other hand, sections of renal medulla revealed normal appearance for normal doses while renal cortex and medulla were showed marked interstitial nephritis, which characterized by interstitial thickening due to infiltration of mono nuclear leukocytes and the renal tubules showed sever vacular degeneration and necrosis for double doses. These results can guide the safe use of favipiravir and reduce the risks to tissue the liver and kidney by using double doses.
ABSTRACT
Venetian quarantine 400 years ago was an important public health measure. Since 1900 this has been refined to include "challenge" or deliberate infection with pathogens be they viruses, bacteria, or parasites. Our focus is virology and ranges from the early experiments in Cuba with Yellow Fever Virus to the most widespread pathogen of our current times, COVID-19. The latter has so far caused over four million deaths worldwide and 190 million cases of the disease. Quarantine and challenge were also used to investigate the Spanish Influenza of 1918 which caused over 100 million deaths. We consider here the merits of the approach, that is the speeding up of knowledge in a practical sense leading to the more rapid licensing of vaccines and antimicrobials. At the core of quarantine and challenge initiatives is the design of the unit to allow safe confinement of the pathogen and protection of the staff. Most important though is the safety of volunteers. We can see now, as in 1900, that members of our society are prepared and willing to engage in these experiments for the public good. Our ethnology study, where the investigator observed the experiment from within the quarantine, gave us the first indication of changing attitudes amongst volunteers whilst in quarantine. These quarantine experiments, referred to as challenge studies, human infection studies, or "controlled human infection models" involve thousands of clinical samples taken over two to three weeks and can provide a wealth of immunological and molecular data on the infection itself and could allow the discovery of new targets for vaccines and therapeutics. The Yellow Fever studies from 121 years ago gave the impetus for development of a successful vaccine still used today whilst also uncovering the nature of the Yellow Fever agent, namely that it was a virus. We outline how carefully these experiments are approached and the necessity to have high quality units with self-contained air-flow along with extensive personal protective equipment for nursing and medical staff. Most important is the employment of highly trained scientific, medical and nursing staff. We face a future of emerging pathogens driven by the increasing global population, deforestation, climate change, antibiotic resistance and increased global travel. These emerging pathogens may be pathogens we currently are not aware of or have not caused outbreaks historically but could also be mutated forms of known pathogens including viruses such as influenza (H7N9, H5N1 etc.) and coronaviruses. This calls for challenge studies to be part of future pandemic preparedness as an additional tool to assist with the rapid development of broad-spectrum antimicrobials, immunomodulators and new vaccines.
ABSTRACT
In January 2022, a total of 68 infectious diseases were reported globally, affecting 228 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were corona virus disease 2019 (COVID-19, 228), dengue fever (26), measles (19), cholera (12) and leptospirosis (10). The top five infectious diseases with highest case fatality rates were Rift Valley fever (100.0%), Lassa fever (19.0%), yellow fever (15.5%), plague (7.5%) and West Nile fever (7.1%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, measles, Lassa fever and cholera. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, cholera, yellow fever, Lassa fever, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever and chikungunya fever, the prevalent infectious disease in Europe was COVID-19.
ABSTRACT
In December 2021, a total of 64 infectious diseases were reported globally, affecting 228 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were corona virus disease 2019 (COVID-19, 228), measles (29), dengue fever (28), cholera (12) and chikungunya fever (9). The top five infectious diseases with highest case fatality rates were Ebola virus disease (81.8%), Middle East respiratory syndrome (34.4%), yellow fever (22.0%), Lassa fever (20.0%) and plague (10.8%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, measles, dengue fever and cholera. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, cholera, yellow fever, plague, Lassa fever, poliomyelitis, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever, chikungunya fever and Zika virus disease, the prevalent infectious disease in Europe was COVID-19.
ABSTRACT
In November 2021, a total of 65 infectious diseases were reported globally, affecting 226 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were Corona virus disease 2019 (COVID-19, 226), dengue fever (31), measles (21), poliomyelitis (11) and cholera (10). The top five infectious diseases with highest case fatality rates were Ebola virus disease (81.8%), Lassa fever (18.6%), yellow fever (15.3%), meningitis (7.9%) and plague (7.6%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, cholera, dengue fever and yellow fever. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, Ebola virus disease, cholera, yellow fever, Lassa fever, poliomyelitis, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever, chikungunya fever and Zika virus disease, the prevalent infectious disease in Europe were COVID-19 and West Nile fever.
ABSTRACT
The Democratic Republic of Congo recorded its first case of the novel coronavirus (COVID-19) in the country on March 10th, 2020. The pandemic arrived in a country that was simultaneously battling its 10th Ebola outbreak, Yellow fever, and ongoing conflict. In other to mitigate the spread of COVID-19 with a health system already under severe pressure from other infectious diseases, the national government declared a state of health emergency, and a nationwide lockdown. Although these measures were instituted to mitigate the outbreak and help maintain an overburdened health system, it also contributed to an increase in anxiety, fear of economic down-turn and a worsening precarious situation, creating a confluence of disaster, conflict and disease. Using both qualitative and secondary sources for data gathering, this study analyses all factors involved in understanding conflict, disease and disaster in the Democratic Republic of Congo by analyzing government responses, top down measures and external interventions, revealing issues of police brutality, human rights and gender inequality. The study also discovered disaster coping mechanism employed by people living in the Kivu's and how these coping mechanisms are helping to maintain hope and mental sanity in a precarious conflict state.
ABSTRACT
In October 2021, a total of 60 infectious diseases were reported globally, affecting 226 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were corona virus disease 2019 (COVID-19, 226), dengue fever (24), measles (24), cholera (10) and malaria (9). The top five infectious diseases with highest case fatality rates were Ebola virus disease (75.0%), Lassa fever (19.7%), meningitis (8.5%), plague (7.6%) and West Nile fever (5.7%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, cholera, dengue fever and meningitis. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, Ebola virus disease, cholera, yellow fever, lassa fever, poliomyelitis, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever, chikungunya fever and Zika virus disease, the prevalent infectious disease in Europe were COVID-19 and West Nile fever.
ABSTRACT
In September 2021, a total of 63 infectious diseases were reported globally, affecting 226 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were Corona virus disease 2019(COVID-19, 226), dengue fever (28), measles (26), West Nile fever (10) and cholera (9). The top five infectious diseases with highest case fatality rates were Nipah virus disease (100.0%), Middle East respiratory syndrome (34.4%), Lassa fever (20.3%), plague (20.0%) and meningitis (15.8%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, cholera, meningitis and dengue fever. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, cholera, plague, yellow fever, Lassa fever, poliomyelitis, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever and chikungunya fever, the prevalent infectious disease in Europe were COVID-19 and West Nile fever.
ABSTRACT
In August 2021, a total of 69 infectious diseases were reported globally, affecting 225 countries and regions. Except for influenza, the top five infectious diseases affecting greatest number of countries and regions were COVID-19 (225), dengue fever (27), measles (21), chikungunya fever (10) and cholera (8). The top five infectious diseases with highest case fatality rates were Marburg virus disease (100.0%), Middle East respiratory syndrome (34.4%), plague (23.3%), Lassa fever (20.5%) and yellow fever (16.7%). The top five infectious diseases with greatest number of deaths were COVID-19, malaria, measles, cholera and dengue fever. The prevalent infectious diseases in Asia were COVID-19 and dengue fever, the prevalent infectious diseases in Africa were COVID-19, Ebola virus disease, Marburg virus disease, cholera, plague, yellow fever, Lassa fever, poliomyelitis, malaria and measles, the prevalent infectious diseases in America were COVID-19, dengue fever and chikungunya fever, the prevalent infectious disease in Europe were COVID-19 and West Nile fever.